DE60017115D1 - Amid-derivate und deren medizinische verwendung - Google Patents

Amid-derivate und deren medizinische verwendung

Info

Publication number
DE60017115D1
DE60017115D1 DE60017115T DE60017115T DE60017115D1 DE 60017115 D1 DE60017115 D1 DE 60017115D1 DE 60017115 T DE60017115 T DE 60017115T DE 60017115 T DE60017115 T DE 60017115T DE 60017115 D1 DE60017115 D1 DE 60017115D1
Authority
DE
Germany
Prior art keywords
halogen
alkyl
hydrogen
compound
medical use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017115T
Other languages
English (en)
Other versions
DE60017115T2 (de
Inventor
Hiroyuki Ushio
Seigo Ishibuchi
Youichiro Naito
Naoki Sugiyama
Takafumi Kawaguchi
Kenji Chiba
Makio Ohtsuki
Yoichi Naka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of DE60017115D1 publication Critical patent/DE60017115D1/de
Application granted granted Critical
Publication of DE60017115T2 publication Critical patent/DE60017115T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE60017115T 1999-02-10 2000-02-10 Amid-derivate und deren medizinische verwendung Expired - Lifetime DE60017115T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP3336799 1999-02-10
JP3336799 1999-02-10
JP19847399 1999-07-13
JP19847399 1999-07-13
PCT/JP2000/000767 WO2000047558A1 (en) 1999-02-10 2000-02-10 Amide compounds and medicinal use thereof

Publications (2)

Publication Number Publication Date
DE60017115D1 true DE60017115D1 (de) 2005-02-03
DE60017115T2 DE60017115T2 (de) 2005-12-08

Family

ID=26372047

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017115T Expired - Lifetime DE60017115T2 (de) 1999-02-10 2000-02-10 Amid-derivate und deren medizinische verwendung

Country Status (16)

Country Link
US (1) US7015218B1 (de)
EP (1) EP1176140B1 (de)
JP (1) JP3419395B2 (de)
KR (1) KR100659007B1 (de)
CN (1) CN1230421C (de)
AT (1) ATE286026T1 (de)
AU (1) AU2460600A (de)
BR (1) BR0008173A (de)
CA (1) CA2362381C (de)
DE (1) DE60017115T2 (de)
ES (1) ES2234564T3 (de)
HK (1) HK1046136A1 (de)
IL (1) IL144826A0 (de)
MX (1) MXPA01008142A (de)
NZ (1) NZ514095A (de)
WO (1) WO2000047558A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU780572B2 (en) * 1999-10-18 2005-04-07 University Of Connecticut, The Pyrazole derivatives as cannabinoid receptor antagonists
MXPA03000923A (es) * 2000-07-31 2003-06-09 Smithkline Beecham Plc Compuestos de carboxamida y su uso como antagonistas de un receptor 11cby humano.
AU2001277731A1 (en) 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
WO2002055100A2 (en) * 2000-10-20 2002-07-18 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
JP2002338537A (ja) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
FR2828488B1 (fr) * 2001-08-08 2005-06-10 Oreal Composition pour la teinture de fibres keratiniques contenant une paraphenylenediamine substituee par un radical diazacycloheptane
EP1944304B1 (de) * 2001-08-13 2012-11-28 E.I. Du Pont De Nemours And Company Neuartige substituierte 1H-Dihydropyrazole, ihre Zubereitung und Verwendung
US7038057B2 (en) 2001-08-13 2006-05-02 E.I. Du Pont De Nemours And Company Substituted 1H-dihydropyrazoles, their preparation and use
EP1417204B1 (de) 2001-08-15 2006-01-18 E. I. du Pont de Nemours and Company Mit heterocyclen ortho-substituierte aryl amide zur bekämpfung wirbelloser schädlinge
RU2330839C2 (ru) 2002-01-11 2008-08-10 Санкио Компани, Лимитед Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные
HRP20050092A2 (en) * 2002-06-29 2005-02-28 Zentaris Gmbh Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
EP1565150A1 (de) * 2002-11-20 2005-08-24 L'oreal Verwendung eines pyrazolcarboxamidderivates zur stimulation von keratinischem faserwachstum und/oder zur verhinderung von dessen verlust
FR2847160A1 (fr) * 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
CN1732155A (zh) * 2002-12-27 2006-02-08 三共农业株式会社 4-氨基-5-甲基吡唑衍生物及其制备方法
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
ATE482747T1 (de) * 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
EP1854487A3 (de) * 2003-04-11 2010-09-22 High Point Pharmaceuticals, LLC Kombinationspräparate welche einen 11-beta-Hydroxysteroiddehydrogenase Typ-1 Hemmer und einen Agonist des Glucocorticoidrezeptors enthalten
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
ES2350837T3 (es) 2003-05-01 2011-01-27 Bristol-Myers Squibb Company Compuestos de pirazol-amida sustituidos con arilo útiles como inhibidores de quinasas.
WO2004110998A1 (en) 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
DE10325439A1 (de) * 2003-05-21 2004-12-09 Bayer Cropscience Ag Iodpyrazolylcarboxanilide
TWI355934B (en) 2004-02-24 2012-01-11 Sankyo Co Pharmaceutical composition for treatment or prophy
EP1568698A1 (de) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrolderivate als faktor-xa-inhibitoren
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US8026237B2 (en) * 2004-07-30 2011-09-27 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
GB0421908D0 (en) * 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
BRPI0614141A2 (pt) * 2005-08-05 2016-11-22 Basf Se composto, composição fungicida, uso de compostos, método para controlar fungos nocivos fitopatogênicos, e, semente
US7406394B2 (en) 2005-08-22 2008-07-29 Applied Materials, Inc. Spectra based endpointing for chemical mechanical polishing
WO2007052843A1 (ja) * 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DK2116530T3 (da) * 2007-02-26 2013-01-28 Santen Pharmaceutical Co Ltd Nyt pyrrolderivat, der har en ureidgruppe og en aminobonylgruppe som substituenter
US20090023731A1 (en) * 2007-03-22 2009-01-22 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US20090099201A1 (en) * 2007-05-22 2009-04-16 David Robert Bolin Diacylglycerol Acyltransferase Inhibitors
US8058299B2 (en) * 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8153644B2 (en) 2007-05-22 2012-04-10 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8115011B2 (en) * 2007-05-22 2012-02-14 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP5602349B2 (ja) * 2007-11-20 2014-10-08 旭化成ファーマ株式会社 ミゾリビン及び/又はリバビリンの測定方法
BRPI0912245A2 (pt) 2008-03-05 2019-09-24 Takeda Pharmaceuticals Co composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
WO2009153592A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
US8211884B2 (en) 2008-08-06 2012-07-03 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EP2356090B1 (de) * 2008-11-11 2017-07-05 Novartis AG Kristalline formen von fingolimod hcl
US8211914B2 (en) 2008-12-17 2012-07-03 Madrigal Pharmaceuticals, Inc. Inhibitors of diacylglycerol acyltransferase
US8946231B2 (en) 2009-03-23 2015-02-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
EP2236505A1 (de) 2009-04-03 2010-10-06 Bayer CropScience AG Acylierte Aminopyridine und - pyridazine als Insektizide
US8669259B2 (en) * 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
CN102127065B (zh) * 2010-05-19 2014-02-12 江苏省农药研究所股份有限公司 邻杂环甲酰取代苯胺类化合物及其合成方法和应用
KR20140000695A (ko) 2010-10-14 2014-01-03 미쓰비시 타나베 파마 코퍼레이션 아미드 유도체 및 그 용도
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
SI2635299T1 (sl) * 2010-11-02 2020-02-28 The Trustees Of Columbia University In The City Of New York Postopki za zdravljenje motenj izgube las
FR2974576B1 (fr) 2011-04-29 2013-07-19 Sanofi Aventis Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique
WO2013020069A1 (en) 2011-08-03 2013-02-07 Ma Zhongmin Treatment of type 2 diabetes with fty720
ES2694681T3 (es) * 2012-03-29 2018-12-26 The Trustees Of Columbia University In The City Of New York Métodos para tratar trastornos de pérdida capilar
AU2013247671A1 (en) * 2012-04-13 2014-10-23 Mitsubishi Tanabe Pharma Corporation Amidopyridine derivative, and use thereof
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
EP2943197A1 (de) 2013-01-10 2015-11-18 Grünenthal GmbH Pyrazolylbasierte carboxamide ii als crac-kanal-hemmer
EP2943196A1 (de) 2013-01-10 2015-11-18 Grünenthal GmbH Pyrazolylbasierte carboxamide i als crac-kanal-hemmer
JP2015096499A (ja) * 2013-10-11 2015-05-21 田辺三菱製薬株式会社 医薬組成物
WO2015090580A1 (en) * 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides useful as calcium release activated calcium channel (icrac) inhibitors
WO2015090579A1 (en) * 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
LT3113772T (lt) 2014-03-07 2020-12-28 Biocryst Pharmaceuticals, Inc. Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
WO2015197187A1 (en) 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides v
WO2015197188A1 (en) * 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides as crac inhibitors
CN104829592B (zh) * 2015-05-22 2017-03-15 河南科技大学第一附属医院 4‑哌啶基‑1h‑吡咯‑3‑甲酰胺类化合物盐酸盐的合成方法
WO2019067530A1 (en) * 2017-09-26 2019-04-04 The Broad Institute, Inc. COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY INTESTINAL DISEASE
JP7296408B2 (ja) * 2018-06-18 2023-06-22 ヤンセン ファーマシューティカ エヌ.ベー. Malt1阻害剤としてのピラゾール誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046775A (en) 1973-04-11 1977-09-06 Sterling Drug Inc. 4,5-Dihalopyrrole-2-carboxamides
US4134987A (en) * 1976-01-14 1979-01-16 Huppatz John L Compounds and compositions
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
FR2662692B1 (fr) 1990-05-30 1995-04-28 Novapharme Derives heterocycliques doues d'activite anticonvulsivante, procede de preparation et composition pharmaceutique.
US5368854A (en) * 1992-08-20 1994-11-29 Schering Corporation Use of IL-10 to treat inflammatory bowel disease
NZ255757A (en) 1992-08-20 1997-07-27 Schering Corp Compositions and methods for the use of il-4 and/or il-10 and antibodies against these cytokines
WO1994004180A2 (en) 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6020121A (en) 1995-09-29 2000-02-01 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
EP1068187A1 (de) * 1998-04-08 2001-01-17 Abbott Laboratories Pyrazole als inhibitoren der cytokinproduktion

Also Published As

Publication number Publication date
EP1176140A1 (de) 2002-01-30
IL144826A0 (en) 2002-06-30
KR100659007B1 (ko) 2007-02-28
AU2460600A (en) 2000-08-29
CA2362381A1 (en) 2000-08-17
HK1046136A1 (zh) 2002-12-27
WO2000047558A1 (en) 2000-08-17
CN1346348A (zh) 2002-04-24
JP3419395B2 (ja) 2003-06-23
EP1176140A4 (de) 2002-07-31
KR20010102040A (ko) 2001-11-15
CA2362381C (en) 2009-12-22
US7015218B1 (en) 2006-03-21
NZ514095A (en) 2001-09-28
BR0008173A (pt) 2002-10-22
CN1230421C (zh) 2005-12-07
ES2234564T3 (es) 2005-07-01
DE60017115T2 (de) 2005-12-08
EP1176140B1 (de) 2004-12-29
ATE286026T1 (de) 2005-01-15
MXPA01008142A (es) 2003-07-21

Similar Documents

Publication Publication Date Title
ATE286026T1 (de) Amid-derivate und deren medizinische verwendung
DE69829875D1 (de) Piperazin-verbindungen und ihre medizinische verwendung
ATE180468T1 (de) Anthranilsäure derivate
NO970892L (no) Isoksazolderivater
DE69205327D1 (de) Harnstoffderivate, Verfahren zu ihrer Herstellung und diese enthaltende Medikamente.
BR9103433A (pt) Derivados de 4-benzil-isoxazol
ATE334975T1 (de) Sulfonamidderivate, ihre herstellung und verwendung
BR0207846A (pt) Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
DE69803750D1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
DE60130119D1 (de) Phenylpyridazinderivate und diese enthaltende arzneimittel
FR2707645B1 (fr) Dérivés d'imidazo[1,2-a]pirazine-4-one, leur préparation et les médicaments les contenant.
PT801062E (pt) Derivados de pirimidina
PT852226E (pt) Derivados de pirimidina
DE69832614D1 (de) Benzopyranderivate zur behandlung von perihperer gefässerkrankung
DE69523819D1 (de) Quinolin-Derivate und diese enthaltende pharmazeutische Zusammensetzungen
RU94038051A (ru) Гетероциклические производные, способ их получения, фармацевтическая композиция и способ лечения
ATE336496T1 (de) Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
MX9604347A (es) Derivados del acido 2-(4-pirazoliloxi-pirimidin-5-il) acetico.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition